2024
Patterns of Care for T1 Glottic Squamous Cell Carcinomas from 2004–2020
Malik D, Jacobs D, Fereydooni S, Park H, Mehra S. Patterns of Care for T1 Glottic Squamous Cell Carcinomas from 2004–2020. The Laryngoscope 2024, 134: 3633-3644. PMID: 38411338, DOI: 10.1002/lary.31363.Peer-Reviewed Original ResearchGlottic squamous cell carcinomaT1 glottic squamous cell carcinomaSquamous cell carcinomaDual-modality treatmentOver-treatmentT1a tumorsCell carcinomaTreatment regimensOverall treatment modalityNational Cancer DatabaseRate of surgeryYear of treatmentMultivariate logistic regressionCochran-Armitage testT1b tumorsT1b diseaseCancer DatabaseOver-treatedTreatment modalitiesTreatment patternsAssociated with greater likelihoodSurgeryPatientsTumorLogistic regression
2021
Combinations of immunotherapy and radiation therapy in head and neck squamous cell carcinoma: a narrative review
Hayman TJ, Bhatia AK, Jethwa KR, Young MR, Park HS. Combinations of immunotherapy and radiation therapy in head and neck squamous cell carcinoma: a narrative review. Translational Cancer Research 2021, 10: 2571-2585. PMID: 35116571, PMCID: PMC8798834, DOI: 10.21037/tcr-20-2096.Peer-Reviewed Original ResearchNeck squamous cell carcinomaSquamous cell carcinomaRadiation therapyCell carcinomaImmune responseNon-surgical treatment modalitiesCell death ligand 1Cell death protein 1Cancer-directed therapyCombination of immunotherapyAnti-tumor responseDeath ligand 1Death protein 1Adaptive immune responsesAdaptive immune systemAdvanced HNSCCAdvanced diseaseMetastatic settingPostoperative settingSystemic therapyImmunomodulatory effectsTreatment modalitiesRecurrent/Clinical trialsClinical data
2020
Association of Neoadjuvant Treatment Modality with Negative Margin and Pathologic Downstaging in Patients Undergoing Pancreatic Cancer Resection: A National Cancer Database Analysis
Miccio J, Mokhtech M, Jabbour S, Anker C, Patel T, Park H, Cecchini M, Salem R, Kuntsman J, Stein S, Kortmansky J, Lacy J, Narang A, Herman J, Haddock M, Hallemeier C, Johung K, Jethwa K. Association of Neoadjuvant Treatment Modality with Negative Margin and Pathologic Downstaging in Patients Undergoing Pancreatic Cancer Resection: A National Cancer Database Analysis. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e662. DOI: 10.1016/j.ijrobp.2020.07.1980.Peer-Reviewed Original ResearchQuantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients
Miccio JA, Talcott WJ, Jairam V, Park HS, Yu JB, Leapman MS, Johnson SB, King MT, Nguyen PL, Kann BH. Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients. Prostate Cancer And Prostatic Diseases 2020, 24: 414-422. PMID: 32989262, DOI: 10.1038/s41391-020-00291-3.Peer-Reviewed Original ResearchConceptsProstate cancer-specific survivalLow-risk prostate cancerExternal beam radiotherapyTreatment selection biasOverall survivalRadical prostatectomyProstate cancerOS differenceLow-risk prostate cancer patientsCancer-specific survivalEnd Results (SEER) databaseProstate cancer patientsClinical trial designEffectiveness researchComparative effectiveness researchPropensity-score matchingMethodsThe SurveillanceTreatment guidelinesResults databaseEntire cohortResultsA totalCancer patientsTreatment modalitiesNational registryPatient management
2018
Impact of Health Insurance Status on Prostate Cancer Treatment Modality Selection in the United States
Bledsoe T, Park H, Rutter C, Aneja S, Nguyen PL, Yu J. Impact of Health Insurance Status on Prostate Cancer Treatment Modality Selection in the United States. American Journal Of Clinical Oncology 2018, 41: 1062-1068. PMID: 29521648, DOI: 10.1097/coc.0000000000000423.Peer-Reviewed Original ResearchTreatment modality selectionInsurance statusTreatment modalitiesProstate cancerPrivate insuranceProstate cancer treatment modalitiesMultivariable logistic regression analysisInvasive surgeryModality selectionCancer-directed treatmentD'Amico risk classificationTreatment modality choiceNational Cancer DatabaseLocalized prostate cancerPatient insurance statusExternal beam radiotherapyLogistic regression analysisHealth insurance statusStrongest predictorMen ages 18Cancer treatment modalitiesClinical factorsMultivariable analysisActive surveillanceCancer Database
2014
Effect of Primary Treatment Modality on the Association Between Statins and Prostate Cancer Recurrence: An Updated Meta-analysis
Park H, Schoenfeld J, Vega R, Shive M, Hartman R, Ogembo R, Mucci L. Effect of Primary Treatment Modality on the Association Between Statins and Prostate Cancer Recurrence: An Updated Meta-analysis. International Journal Of Radiation Oncology • Biology • Physics 2014, 90: s408. DOI: 10.1016/j.ijrobp.2014.05.1297.Peer-Reviewed Original Research
2013
Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: a systematic review and meta-analysis
Park HS, Schoenfeld JD, Mailhot RB, Shive M, Hartman RI, Ogembo R, Mucci LA. Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: a systematic review and meta-analysis. Annals Of Oncology 2013, 24: 1427-1434. PMID: 23508824, PMCID: PMC3660083, DOI: 10.1093/annonc/mdt077.Peer-Reviewed Original ResearchConceptsRecurrence-free survivalPrimary treatment modalityLocalized prostate cancerEffect of statinsRadical prostatectomy patientsProstate cancer recurrenceHazard ratioProstatectomy patientsTreatment modalitiesRadical prostatectomyCancer recurrenceProstate cancerProstate cancer patientsOncologic outcomesDefinitive treatmentRT patientsCancer patientsEmbase databasesEligible studiesStatinsPatientsSystematic reviewRadiotherapyBeneficial effectsSystematic search